Clinical Benefit of Zoledronic Acid for the Prevention of Skeletal Complications in Advanced Prostate Cancer

Saad, Fred

doi:10.3816/cgc.2005.n.009

Cited by 52 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent clinical studies have revealed that bisphosphonate, which functions to block bone destruction, reduces, delays and relieves prostate cancer to bone metastasis (Saad et al, 2002(Saad et al, , 2004Saad, 2005). These results suggest that osteoclast-driven bone resorption is an important target for treatment of prostate cancer to bone metastasis.…”

Section: Discussionmentioning

confidence: 80%

Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1

Chan

et al. 2009

Br J Cancer

View full text Add to dashboard Cite

BACKGROUND: Id-1 is overexpressed in and correlated with metastatic potential of prostate cancer. The role of Id-1 in this metastatic process was further analysed. METHODS: Conditioned media from prostate cancer cells, expressing various levels of Id-1, were used to stimulate pre-osteoclast differentiation and osteoblast mineralisation. Downstream effectors of Id-1 were identified. Expressions of Id-1 and its downstream effectors in prostate cancers were studied using immunohistochemistry in a prostate cancer patient cohort (N ¼ 110). RESULTS: We found that conditioned media from LNCaP prostate cancer cells overexpressing Id-1 had a higher ability to drive osteoclast differentiation and a lower ability to stimulate osteoblast mineralisation than control, whereas conditioned media from PC3 prostate cancer cells with Id-1 knockdown were less able to stimulate osteoclast differentiation. Id-1 was found to negatively regulate TNF-b and this correlation was confirmed in human prostate cancer specimens (P ¼ 0.03). Furthermore, addition of recombinant TNF-b to LNCaP Id-1 cell-derived media blocked the effect of Id-1 overexpression on osteoblast mineralisation. CONCLUSION: In prostate cancer cells, the ability of Id-1 to modulate bone cell differentiation favouring metastatic bone disease is partially mediated by TNF-b, and Id-1 could be a potential therapeutic target for prostate cancer to bone metastasis.

show abstract

Section: Discussionmentioning

confidence: 80%

Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1

Chan

et al. 2009

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Bisphosphonates also have antiangiogenesis properties (8,9) and can activate ␥␦ T cells (10,11). The use of bisphosphonates in patients with multiple myeloma and metastatic cancer to the bones, such as breast, prostate, lung, and renal cell carcinomas, has resulted in a statistically significant reduction in skeletal complications, including pathologic fractures, spinal cord compression, hypercalcemia of malignant disease, and the need for subsequent radiotherapy or surgery to bone (12)(13)(14). Intravenous bisphosphonates have improved bioavailability and do not produce gastrointestinal side effects, resulting in better patient adherence.…”

Section: Actions Of Bisphosphonatesmentioning

confidence: 99%

Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

2006

View full text Add to dashboard Cite

Osteonecrosis of the jaws is a recently described adverse side effect of bisphosphonate therapy. Patients with multiple myeloma and metastatic carcinoma to the skeleton who are receiving intravenous, nitrogen-containing bisphosphonates are at greatest risk for osteonecrosis of the jaws; these patients represent 94% of published cases. The mandible is more commonly affected than the maxilla (2:1 ratio), and 60% of cases are preceded by a dental surgical procedure. Oversuppression of bone turnover is probably the primary mechanism for the development of this condition, although there may be contributing comorbid factors. All sites of potential jaw infection should be eliminated before bisphosphonate therapy is initiated in these patients to reduce the necessity of subsequent dentoalveolar surgery. Conservative débridement of necrotic bone, pain control, infection management, use of antimicrobial oral rinses, and withdrawal of bisphosphonates are preferable to aggressive surgical measures for treating this condition. The degree of risk for osteonecrosis in patients taking oral bisphosphonates, such as alendronate, for osteoporosis is uncertain and warrants careful monitoring.

show abstract

“…Our case series is much larger than most of the above works incidence rate of 0.8% was observed, which is lower than ours (1.5%, 95% CI, 0.7%-2.8%). Furthermore, of the eight cases of ONJ we observed, four were diagnosed several months after interruption of bisphosphonate treatment (median, 8.5 months; range, [5][6][7][8][9][10][11][12][13]. This would seem to indicate that the drug is still present in bone tissue months after its suspension.…”

Section: Discussionmentioning

confidence: 99%

“…Five hundred fifteen patients were treated with ZA, receiving a mean of 6.7 cycles (range, 1-65). PA was administered to eight patients, who received a mean of 2.8 cycles (range, [1][2][3][4][5][6][7][8]. Sixteen patients were given both PA and ZA, with a mean of two cycles (range, 1-7) and 11 cycles (range, 2-34) administered, respectively ( Table 2).…”

Section: Resultsmentioning

confidence: 99%

Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study

et al. 2008

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Discuss the importance of treating patients with bone metastases using a multidisciplinary approach.2. Explain why bisphosphonates are a fundamental part of bone metastasis treatment.3. Evaluate the main features of ONJ and, in particular, its high risk factor. 4. Describe the importance of ONJ prevention during bisphosphonate treatment.5. Emphasize the importance of interaction among the patient's dentist, surgeon, and oncologist for the management of ONJ.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME Results. The eight patients with ONJ had all been given zoledronic acid, and two had also been treated with pamidronic acid. In four of the patients, ONJ was diagnosed during treatment, while in the remaining four it was diagnosed several months after therapy with bisphosphonates had ended. Six of these patients received local noninvasive treatment, of whom five progressed. Two showed apparent autolimitation of the disease. The remaining two patients underwent surgical resection and currently show no signs of relapse. All eight ONJ patients presented with various concomitant risk factors such as paradontopathy, dental extraction, or spontaneous avulsion. ABSTRACTConclusions. Our results show that ONJ can appear months after interruption of treatment and that a surgical approach can be used in suitable cases. Closer cooperation is needed among specialists to define guidelines for the prevention of ONJ in patients with bone metastases. The Oncologist 2008;13:330 -336

show abstract

Clinical Benefit of Zoledronic Acid for the Prevention of Skeletal Complications in Advanced Prostate Cancer

Cited by 52 publications

References 30 publications

Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1

Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1

Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study

Contact Info

Product

Resources

About